Caprock Group LLC Buys New Holdings in ASP Isotopes Inc. $ASPI

Caprock Group LLC purchased a new position in shares of ASP Isotopes Inc. (NASDAQ:ASPI) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 296,000 shares of the company’s stock, valued at approximately $2,747,000. Caprock Group LLC owned 0.32% of ASP Isotopes as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Rovida Advisors Inc. bought a new position in shares of ASP Isotopes during the 2nd quarter worth approximately $16,148,000. Rovida Investment Management Ltd lifted its holdings in ASP Isotopes by 528.6% during the 2nd quarter. Rovida Investment Management Ltd now owns 2,200,000 shares of the company’s stock valued at $16,148,000 after purchasing an additional 1,850,000 shares during the last quarter. Sara Bay Financial bought a new position in ASP Isotopes during the third quarter worth $8,688,000. Invesco Ltd. increased its holdings in shares of ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after purchasing an additional 450,776 shares during the last quarter. Finally, Creative Planning bought a new position in shares of ASP Isotopes in the second quarter valued at about $1,272,000. Institutional investors own 16.80% of the company’s stock.

ASP Isotopes Trading Down 9.5%

Shares of NASDAQ:ASPI opened at $5.13 on Friday. The business’s 50 day simple moving average is $6.42 and its 200 day simple moving average is $8.18. ASP Isotopes Inc. has a 1 year low of $3.65 and a 1 year high of $14.49. The company has a debt-to-equity ratio of 1.04, a current ratio of 6.14 and a quick ratio of 6.10. The company has a market capitalization of $568.61 million, a P/E ratio of -3.95 and a beta of 3.47.

ASP Isotopes (NASDAQ:ASPI) last released its earnings results on Wednesday, November 19th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.05). The company had revenue of $4.89 million for the quarter, compared to the consensus estimate of $2.25 million. ASP Isotopes had a negative net margin of 1,259.12% and a negative return on equity of 190.44%. On average, research analysts anticipate that ASP Isotopes Inc. will post -0.24 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Chairman Paul Elliot Mann sold 162,153 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $5.75, for a total value of $932,379.75. Following the completion of the transaction, the chairman directly owned 7,759,538 shares in the company, valued at approximately $44,617,343.50. The trade was a 2.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Heather Kiessling sold 80,000 shares of the company’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $5.80, for a total transaction of $464,000.00. Following the sale, the chief financial officer directly owned 732,500 shares of the company’s stock, valued at approximately $4,248,500. This trade represents a 9.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 505,591 shares of company stock valued at $3,233,245 over the last quarter. 14.40% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on ASPI shares. Cantor Fitzgerald initiated coverage on shares of ASP Isotopes in a report on Thursday, December 4th. They set an “overweight” rating and a $13.00 target price for the company. Loop Capital set a $15.00 price objective on ASP Isotopes in a report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ASP Isotopes in a research report on Monday, December 29th. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $11.00 price target on shares of ASP Isotopes in a report on Monday, November 24th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ASP Isotopes currently has an average rating of “Hold” and an average target price of $13.00.

About ASP Isotopes

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.